BIMEKIZUMAB EFFICACY BY BODY REGION IN PLAQUE PSORIASIS: COMPARATIVE ANALYSES FROM FOUR PHASE 3/3B STUDIES

被引：0
|
作者：
Savage, Laura [1 ]
Pinter, Andreas [2 ]
Crowley, Jeffrey [3 ]
Kerkhof, Peter van de [4 ]
Armstrong, April [5 ]
Kavanagh, Sarah [6 ]
Wiegratz, Susanne [7 ]
Hoepken, Bengt [7 ]
Warren, Richard B. [8 ,9 ]
机构：
[1] Leeds Teaching Hosp NHS Trust, Leeds, England
[2] Univ Hosp Frankfurt, Frankfurt, Germany
[3] Bakersfield Dermatol, Bakersfield, CA USA
[4] Radboud Univ Nijmegen, Nijmegen, Netherlands
[5] Univ Calif Los Angeles UCLA, Los Angeles, CA USA
[6] UCB Pharm, Morrisville, NY USA
[7] UCB Pharm, Monheim, Germany
[8] Northern Care Alliance NHS Fdn Trust, Dermatol Ctr, Manchester, England
[9] Manchester Univ NHS Fdn Trust, NIHR Manchester Biomed Res Ctr, Manchester Acad Hlth Sci Ctr, Manchester Acad Hlth Sci Ctr Manchester, Manchester, England
来源：
ACTA DERMATO-VENEREOLOGICA | 2024年 / 104卷
关键词：
DOUBLE-BLIND; MULTICENTER; MODERATE; SAFETY;
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P-061
引用
收藏
页数：102
相关论文
共 50 条
  • [41] A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasis
    Spelman, Lynda
    Rubel, Diana
    Brnabic, Alan
    Burkhardt, Nicole
    Riedl, Elisabeth
    Foley, Peter
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (01) : 329 - 335
  • [42] BIMEKIZUMAB EFFICACY IN HIGH-IMPACT AREAS FOR PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: POOLED RESULTS THROUGH TWO YEARS FROM THE BE SURE AND BE RADIANT PHASE 3 TRIALS
    Merola, J. F.
    Gottlieb, A. B.
    Morita, A.
    Carrascosa, J. M.
    Elewski, B.
    Tilt, N.
    Wiegratz, S.
    Wixted, K.
    Mrowietz, U.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1766 - 1767
  • [43] Bimekizumab Efficacy and Safety Through 4 Years in Moderate to Severe Plaque Psoriasis: Long-Term Results from a Phase 3 Study and Open-Label Extension
    Thaci, Diamant
    Puig, Luis
    Merola, Joseph F.
    Jullien, Denis
    Costanzo, Antonio
    Wang, Maggie
    Deherder, Delphine
    Lopez Pinto, Jose M.
    Lebwohl, Mark
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4733 - 4735
  • [44] Secukinumab is efficacious in the treatment of moderate to severe plaque psoriasis regardless of sex of subjects: Pooled analysis from four phase 3 studies
    Spelman, L.
    Griffiths, C.
    Gong, Y.
    Fox, T.
    Papavassilis, C.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2016, 57 : 74 - 75
  • [45] A randomized phase 3b study evaluating the safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with non-pustular palmoplantar involvement
    Lebwohl, Mark
    Bukhalo, Michael
    Gold, Linda Stein
    Glick, Brad
    Llamas-Velasco, Mar
    Sanchez-Rivera, Samuel
    Pan, Anqi
    Zhan, Tianyu
    Drogaris, Leonidas
    Douglas, Kevin
    St John, Greg
    Espaillat, Ramon
    Bissonnette, Robert
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 91 (06) : 1150 - 1157
  • [46] IXEKIZUMAB IMPROVES IMPACT OF GENITAL PSORIASIS ON SEXUAL ACTIVITY: RESULTS FROM A PHASE 3B STUDY
    Cather, Jennifer Clay
    Meeuwis, Kim
    Burge, Russel
    Bleakman, Alison Potts
    Lin, Chen-Yen
    Gottlieb, Alice
    Ryan, Catriona
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 11 - 11
  • [47] Bimekizumab in patients with moderate to severe plaque psoriasis: Injection site reactions through two years of the BE RADIANT phase 3b trial and open-label extension with one-year comparison to secukinumab
    Soung, Jennifer
    Rosmarin, David
    Ferrer, Anna Lopez
    Lain, Edward
    Rich, Phoebe
    White, Katy
    Staelens, Fabienne
    Szilagyi, Balint
    Deherder, Delphine
    Magnolo, Nina
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB128 - AB128
  • [48] Relationships between tildrakizumab dose, exposure, efficacy and safety in phase 3 studies in moderate to severe plaque psoriasis
    Strober, Bruce E.
    Sofen, Howard
    Yamauchi, Paul S.
    Mendelsohn, Alan M.
    Parno, Jeff
    Lowry, Simon
    Rozzo, Stephen J.
    Elewski, Boni E.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB117 - AB117
  • [49] Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial
    Gordon, Kenneth B.
    Foley, Peter
    Krueger, James G.
    Pinter, Andreas
    Reich, Kristian
    Vender, Ronald
    Vanvoorden, Veerle
    Madden, Cynthia
    White, Katy
    Cioffi, Christopher
    Blauvelt, Andrew
    LANCET, 2021, 397 (10273): : 475 - 486
  • [50] Bimekizumab response maintenance up to 1 year in patients with moderate to severe plaque psoriasis: Pooled results from three phase 3 trials
    Blauvelt, Andrew
    Tada, Yayoi
    Iversen, Lars
    Mrowietz, Ulrich
    Lebwohl, Mark
    Wang, Maggie
    Vanvoorden, Veerle
    Cullen, Eva
    Staelens, Fabienne
    Papp, Kim A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB140 - AB140
12345